Cyclopharm (ASX:CYC) Total Liabilities : A$13.66 Mil (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Cyclopharm Total Liabilities?

Cyclopharm's Total Liabilities for the quarter that ended in Dec. 2023 was A$13.66 Mil.

Cyclopharm's quarterly Total Liabilities increased from Dec. 2022 (A$13.01 Mil) to Jun. 2023 (A$14.38 Mil) but then declined from Jun. 2023 (A$14.38 Mil) to Dec. 2023 (A$13.66 Mil).

Cyclopharm's annual Total Liabilities increased from Dec. 2021 (A$12.67 Mil) to Dec. 2022 (A$13.01 Mil) and increased from Dec. 2022 (A$13.01 Mil) to Dec. 2023 (A$13.66 Mil).

Cyclopharm Total Liabilities Historical Data

The historical data trend for Cyclopharm's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclopharm Total Liabilities Chart

Cyclopharm Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

9.32

11.16

12.67

13.01

13.66

Cyclopharm Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Liabilities	Get a 7-Day Free Trial															12.67	12.29	13.01	14.38	13.66

Cyclopharm Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Cyclopharm's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	8.669	+	(4.013	+	-1.0408340855861E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0.902	+	0.071)
	=	13.66

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	45.914	-	32.259
	=	13.66

Cyclopharm's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	8.669	+	(4.013	+	-1.0408340855861E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0.902	+	0.071)
	=	13.66

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	45.914	-	32.259
	=	13.66

Cyclopharm Total Liabilities Related Terms

Thank you for viewing the detailed overview of Cyclopharm's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyclopharm (ASX:CYC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cyclopharm Ltd (ASX:CYC) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Unit 4, 1 The Crescent, Kingsgrove, Sydney, NSW, AUS, 2208

Website

https://cyclopharm.com.au

Cyclopharm Ltd is a company that engages in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development. It operates through the following segments. The Technegas segment involves supplying diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism, and a distributor of products to the diagnostic imaging sector. The Molecular Imaging segment offers to produce radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders, and cardiac disease. The firm generates maximum revenue from the Technegas segment.

Cyclopharm (ASX:CYC) Headlines

No Headlines